Source study found

Story checked

More Men Are Getting MRI Before Prostate Biopsy, but a Major Gap Remains (opens in a new tab)

scitechdaily.com · 2026-09-25

Short answerEvidenceSource

Short answer

Not supported

Not supported.

The study does not answer the story's main claims.

5 not covered

Checked against the study summary. The full text wasn't available, so some details couldn't be settled either way.

Share this check

Follow the evidence trail

The story

More Men Are Getting MRI Before Prostate Biopsy, but a Major Gap Remains

scitechdaily.com · 2026-09-25

The story’s checkable claims.

Read the original story

NewsLink checks it

Not supported

The study doesn't address any of the story's claims. We found the paper, but it doesn't report the details the story leads with.

5 not covered

Open claim evidence

The source study

Trends in Prebiopsy MRI Utilization for Prostate Cancer Detection

JAMA Oncology · 2026

Open source record Open in Tessa

Then inspect each claim

Evidence layer

Claim by claim

Each claim gets a verdict. Expand it to see the evidence directly below.

Reading mode

Scan verdicts. Open evidence only when needed.

Browse by verdict

5 claims in this story

Showing all 5 claimsChoose a verdict to focus the list.

Claim 1 of 5Not coveredMRI use before a first prostate biopsy has risen sharply, but about one-third of men still undergo the procedure without a scan.View evidenceHide evidence

As statedabout one-third

Why this verdict

The abstract-level profile supports only that the study evaluated US temporal trends in prebiopsy prostate MRI use from Jan 2017 to Jun 2026. It does not provide utilization estimates, trend magnitudes, or the proportion lacking MRI. The headline claim that use rose sharply and that about one-third still undergo biopsy without a scan cannot be verified from the abstract.

Study evidence

The study evaluates rates and temporal trends in prebiopsy MRI use among US men undergoing evaluation that led to prostate biopsy between January 2017 and June 2026; the abstract does not report the observed utilization rates or trend estimates.

“This cohort study evaluates rates of magnetic resonance imaging (MRI) use prior to prostate biopsy in the US from January 2017 to June 2026”

Claim 2 of 5Not coveredA new study found that 64% of men undergoing their first biopsy had an MRI beforehand in the first half of 2026, up from 14% in 2017.View evidenceHide evidence

As stated64% in the first half of 2026, up from 14% in 2017

Why this verdict

The paper profile confirms the study period and topic, but the abstract does not report numerical results. The specific figures of 64% in the first half of 2026 and 14% in 2017 for first biopsy patients are not available at abstract depth.

Study evidence

“This cohort study evaluates rates of magnetic resonance imaging (MRI) use prior to prostate biopsy in the US from January 2017 to June 2026”

Claim 3 of 5Not coveredThe shift follows evidence from multiple randomized trials showing that scanning the prostate first and then targeting suspicious areas finds more aggressive cancers.View evidenceHide evidence

Why this verdict

The supplied paper profile describes a retrospective observational cohort study of MRI utilization trends. It does not include background evidence from randomized trials, guideline changes, or a causal explanation for the utilization shift. At abstract depth, this contextual causal framing cannot be verified against the paper profile.

Study evidence

“This cohort study evaluates rates of magnetic resonance imaging (MRI) use prior to prostate biopsy in the US from January 2017 to June 2026”

Claim 4 of 5Not coveredIn men whose previous biopsy had found no cancer, MRI use rose from 38% in 2017 to 67% in the first half of 2026.View evidenceHide evidence

As stated38% to 67%

Why this verdict

The abstract-level profile does not report subgroup-specific MRI utilization rates for men with a prior negative biopsy. The claimed rise from 38% in 2017 to 67% in the first half of 2026 is therefore not verifiable from the supplied abstract profile.

Study evidence

“This cohort study evaluates rates of magnetic resonance imaging (MRI) use prior to prostate biopsy in the US from January 2017 to June 2026”

Claim 5 of 5Not coveredMRI use was lower among men over 80 and those with very high PSA levels, which the article says may reflect reasonable clinical judgment in some cases but still warrants examination.View evidenceHide evidence

Why this verdict

The abstract-level profile does not report subgroup analyses by age, PSA level, or clinical-judgment interpretations. The story’s hedged framing is cautious, but the underlying subgroup finding is not available at this evidence depth.

Study evidence

“This cohort study evaluates rates of magnetic resonance imaging (MRI) use prior to prostate biopsy in the US from January 2017 to June 2026”

Then look for missing context

Context layer

What the story left out

Important study details the story did not include.

Key methodological details are unavailable at abstract depth, including data source, inclusion/exclusion criteria, MRI ascertainment method, and statistical modeling approach.
The story mentions access, insurance, scan quality, and possible clinical judgment, but it does not reflect the paper-profile limitations about missing methods and uncertain outcome ascertainment at abstract depth.
From Retrospective cohort using routinely collected healthcare data

2 things the story did carry across

The paper is a retrospective US cohort study using routinely collected health care data to evaluate prebiopsy prostate MRI utilization over time.
The paper’s available abstract identifies the time window as January 2017 through June 2026 and the outcome as MRI use prior to prostate biopsy for cancer detection.

Then read the study layer

Study layer

Study at a glance

Scan the study first. Expand only the parts you want to inspect.

Pieces of work

Evidence read

study summary

Lead result

secondary data

1Lead resultsecondary dataQuantify temporal trends in prebiopsy prostate MRI utilization in the US (Jan 2017–Jun 2026) among men undergoing evaluation leading to prostate biopsy for cancer detection.Retrospective cohort using routinely collected healthcare dataExpand

In plain English

Retrospective cohort study using US routinely collected healthcare data to quantify temporal trends in use of magnetic resonance imaging (MRI) prior to prostate biopsy for cancer detection between January 2017 and June 2026. The abstract states the study design, objective, setting, and time window but does not provide numerical utilization estimates, sample size, or analytic details.

Key findings

The study evaluates rates and temporal trends in prebiopsy MRI use among US men undergoing evaluation that led to prostate biopsy between January 2017 and June 2026; the abstract does not report the observed utilization rates or trend estimates.

“This cohort study evaluates rates of magnetic resonance imaging (MRI) use prior to prostate biopsy in the US from January 2017 to June 2026”

What this piece can’t prove

Summary is based on title and single-sentence abstract; no numeric results or methodological details are available in the provided text.
Unclear which routinely collected data source was used (claims vs EHR vs registry) and therefore uncertain generalizability and population coverage.

2 further details could not be confirmed from the summary.

Finally, the search trail

Method layer